Purchase this article with an account.
E.R. Thomas, O.Z. Plous, J.W. Kitchens, T.W. Stone, R.D. Isernhagen, W.J. Wood; Visual Acuity and OCT Outcomes in Visual Acuity and OCT Outcomes in Patients Treated With Bevacizumab for Wet Age Related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5235.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the safety and efficacy of intravitreal bevacizumab in the treatment of wet age related macular degeneration.
A retrospective chart review was performed on the medical records of patients diagnosed with choroidal neovascularization secondary to age related macular degeneration treated with intravitreal bevacizumab.
Sixty nine patients with choroidal nevoascularization secondary to age related macular degeneration were injected with bevacizumab intravitreally. Visual acuity and OCT characteristics were analyzed at baseline, as well as at one and three months post–injection (results to be presented). No adverse events occurred.
Bevacizumab is a safe and possibly effective treatment for choroidal neovascularization secondary to wet age related macular degeneration.
This PDF is available to Subscribers Only